publicly traded companies glp-1 receptor agonist manufacturers Oral Non-Peptide Agonists Market Key Players Ozempic Statistics: GLP-1 Weight Loss

Management of cardiovascular diseases in patients with obesity

World J Gastroenterol (2018) 24:336173

Juji A, Godina C, Belting M, Melander O, Juul Holst J, Ahlqvist E, et al

Metabolism (2020) 109:154272

Story Source: Materials provided by WashU Medicine

The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed